<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01312337</url>
  </required_header>
  <id_info>
    <org_study_id>2010-07-252</org_study_id>
    <nct_id>NCT01312337</nct_id>
  </id_info>
  <brief_title>Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Phase II Trial of Gefitinib Monotherapy in Pretreated Patients With Advanced Non-small Cell Lung Cancer Not Harboring Active EGFR Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will examine efficacy and toxicity of gefitinib in Korean patients with
      EGFR wild tumors diagnosed with direct sequence test.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine disease control rate at 8 weeks will be 35% or higher in the the study group</measure>
    <time_frame>6 months after the enrollment of the last patients</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of patients who live longer than 6 months after enrollment</measure>
    <time_frame>6 months after the enrollment of the last patients</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Nonsmall Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Iressa for EGFR wild group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>salvage Iressa therapy for patients with EGFR mutation negative NSCLC patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salvage iressa</intervention_name>
    <description>Iressa 250mg per day until progression</description>
    <arm_group_label>Iressa for EGFR wild group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically proven NSCLC

          -  Ineligibile for curative treatment (namely, stage IIIb or IV)

          -  History of one to three prior systemic chemotherapy tumors without active EGFR
             mutations (exon 19 deletion, L858R mutation in exon 21)

          -  At least one lesion that was unidimensionally measurable by computed tomography (by
             RECIST 1.1)

          -  18 years old or older

          -  Performance status ECOG 0-2

          -  Adequate organ function as evidenced by the following:

               -  Absolute neutrophil count &gt; 1.0 x 109/L

               -  Platelets &gt; 75 x 109/L

               -  Total bilirubin ≤ 1.5 UNL

               -  AST and/or ALT &lt; 5 UNL

               -  Creatinine clearance ≥ 45mL/min

        Exclusion Criteria:

          -  Previous EGFR TKI therapy history

          -  Systemic anticancer therapy within the previous 3 weeks

          -  Other invasive malignancy within the past 2 years except non-melanoma skin cancer, in
             situ cervix cancer, or papillary thyroid cancer

          -  Other concurrent illness that would preclude study participation (severe heart
             disease)

          -  Other concurrent physical condition (e.g., infectious disease) that would preclude
             study participation

          -  Pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Myung-Ju Ahn, Pf</last_name>
    <phone>82-2-3410-3459</phone>
    <email>silkahn@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Myung-Ju Ahn, Pf</last_name>
      <phone>822-3410-3459</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-Ju ahn, Pf</last_name>
      <phone>82-2-3410-3459</phone>
      <email>silkahn@skku.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2011</study_first_posted>
  <last_update_submitted>March 8, 2011</last_update_submitted>
  <last_update_submitted_qc>March 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Myung-Ju Ahn / Professor</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <keyword>gefitinib</keyword>
  <keyword>EGFR mutation negative</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

